Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| ONCY | PRESS-RELEASE | neutral | 4/10 | Oncolytics Biotech presented a trial-in-progress abstract at ESMO 2026 for REO 033, a randomized Phase 2 study of pelare | Oct 20, 2026 |
| JSPR | DEF 14A | neutral | 5/10 | Jasper Therapeutics is holding a special meeting on November 13, 2026, to seek stockholder approval for the issuance of | Oct 20, 2026 |
| CELU | 10-K/A | bearish | 5/10 | Celularity Inc. filed an Amendment No. 1 to its 2025 Form 10-K solely to add Part III information (directors, executive | Oct 20, 2026 |
| MYGN | 8-K | bullish | 7/10 | Myriad Genetics (MYGN) has entered into a definitive asset purchase agreement to sell its Prenatal Health testing busine | Oct 20, 2026 |
| RCUS | 8-K | neutral | 4/10 | Arcus Biosciences presented new clinical data from its ARC-20 platform study of casdatifan in clear cell renal cell carc | Oct 20, 2026 |
| OPTH | 6-K | neutral | 4/10 | Optimi Health Corp. announced completion of an MDMA production batch to supply a proposed Canadian Phase 3 PTSD trial (u | Oct 20, 2026 |
| FLNA | 8-K | bullish | 5/10 | Filana Therapeutics announced that the Fifth Circuit vacated the district court's class certification order in the secur | Oct 20, 2026 |
| PDSB | 8-K | neutral | 3/10 | PDS Biotechnology announced the resignation of four directors (Kamil Ali-Jackson, Stephen Glover, Gregory Freitag, and O | Oct 20, 2026 |
| ALVO | 6-K | bullish | 6/10 | Alvotech announced FDA approval of a new manufacturing process (Process 2.0) for its Humira biosimilar SIMLANDI (adalimu | Oct 20, 2026 |
| LPCN | 8-K | neutral | 2/10 | Lipocine Inc. filed an 8-K on October 20, 2026, solely to disclose that it has updated its corporate presentation used f | Oct 20, 2026 |
| INSM | 8-K | neutral | 3/10 | Insmed appointed Paul Hudson (former CEO of Sanofi and Novartis Pharmaceuticals) and Utpal Koppikar (CFO of Verily Healt | Oct 20, 2026 |
| MBRX | 8-K | neutral | 4/10 | Moleculin Biotech filed an 8-K to announce a 1-for-20 reverse stock split, effective October 20, 2026, reducing outstand | Oct 20, 2026 |
| ODTX | 8-K | bullish | 6/10 | Odyssey Therapeutics presented completed Phase 2a induction results for OD-001, a first-in-class oral RIPK2 scaffolding | Oct 20, 2026 |
| NXTC | SC 13G | neutral | 4/10 | JP Sailing Capital Ltd and its control person Jianping Huang have filed a new Schedule 13G disclosing a 9.9% passive sta | Oct 20, 2026 |
| QNRX | 8-K | bullish | 6/10 | Quoin Pharmaceuticals announced the publication of a peer-reviewed paper in Dermatology and Therapy detailing a pediatri | Oct 20, 2026 |
| IPHA | 6-K | neutral | 2/10 | Innate Pharma filed a 6-K announcing a conference call on November 5, 2026, to provide a business and financial update f | Oct 20, 2026 |
| RADX | 6-K | neutral | 3/10 | Radiopharm Theranostics filed a 6-K reporting that four directors (Bruce Goodwin, Ian Turner, Paul Hopper, Riccardo Cane | Oct 20, 2026 |
| RAPP | 8-K | bullish | 7/10 | Rapport Therapeutics announced positive topline Phase 2 results for RAP-219 in acute bipolar mania, meeting the primary | Oct 20, 2026 |
| GRDX | EFFECT | mixed | 6/10 | The SEC declared GridAI Technologies Corp.'s S-1 registration statement (File No. 333-296288) effective on October 19, 2 | Oct 20, 2026 |
| FBLG | EFFECT | bearish | 5/10 | The SEC declared effective FibroBiologics' shelf registration (File No. 333-284077) on October 19, 2026, under the 1933 | Oct 20, 2026 |
| FBLG | EFFECT | bearish | 5/10 | The SEC declared effective FibroBiologics' registration statement on Form S-1 (File No. 333-280303) on October 19, 2026, | Oct 20, 2026 |
| BCAB | S-1 | bearish | 7/10 | BioAtla, a clinical-stage biopharmaceutical company developing conditionally active biologics (CABs) for solid tumors, f | Oct 19, 2026 |
| BCAB | 8-K | bearish | 6/10 | BioAtla entered into a new Standby Equity Purchase Agreement (SEPA) with Yorkville for up to $40M in common stock, repla | Oct 19, 2026 |
| ANVS | 8-K | neutral | 1/10 | Annovis Bio filed an 8-K to correct a typographical error in its June 17, 2026 proxy statement regarding audit fees. The | Oct 19, 2026 |
| IAM | INSIDER-BUY | bullish | 6/10 | Director Evan Lockwood Rachlin made a single open-market purchase of 718,800 shares of Iambic Therapeutics at $16.00/sha | Oct 19, 2026 |
| CLNN | 8-K | neutral | 3/10 | Clene Inc. entered into a subaward amendment with NYU Grossman School of Medicine for the fourth year of its NIH grant, | Oct 19, 2026 |
| PAHC | SC 13G/A | bearish | 5/10 | Millennium Management LLC filed an amended Schedule 13G disclosing a passive 3.9% stake in Phibro Animal Health Corp as | Oct 19, 2026 |
| IRON | 424B5 | bearish | 6/10 | Disc Medicine is filing a preliminary prospectus supplement for a $350M underwritten public offering of common stock and | Oct 19, 2026 |
| CTY | CLUSTER | bullish | 6/10 | Two 10% owners, including director Robert Nelsen and ARCH Venture Partners XII, LLC, each purchased 170,000 shares of Ci | Oct 19, 2026 |
| CMMB | 6-K | neutral | 3/10 | Chemomab Therapeutics Ltd. filed a 6-K reporting Amendment No. 2 to its Domestication Merger Agreement, which reduces th | Oct 19, 2026 |